- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01432613
Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies (DARWIM)
Study Overview
Status
Intervention / Treatment
Detailed Description
Idiopathic inflammatory myopathies (IIM) are a great concern in acquired muscle illnesses. An appropriate and rapid diagnosis is necessary, because morbidity and mortality are high and as a specific treatment is needed (corticosteroids, immunosuppressant, and "biotherapies").
Currently the use of muscle MRI in departments managing IIM is common. In absence of recommendations fixing their place in the diagnostic phase, the practices observed are extremely heterogeneous. Some systematically order a muscle MRI for patients suspected to suffer from IIM, others hold this examination for patients selected according to non defined criteria, and others sometimes use MRI to follow-up patients. This practices diversity well reflects the lack of data in the literature, making it impossible to appreciate the real contribution of this test. The results published in the great majority of studies are obtained with patients whose IIM diagnosis is already established. The diagnostic accuracy of muscle MRI in real conditions of clinical practice is thus unknown for patients having a simple suspicion of IIM.
Primary scientific aim: Evaluation of diagnostic accuracy of muscle MRI (in terms of sensitivity, specificity, predictive positive value and predictive negative value) for patients who are suspected to suffer from IIM.
Secondary scientific aim: Comparison of two diagnostic strategies: MRI-oriented muscle biopsy versus non MRI-oriented muscle biopsy.
Gold standard: muscle biopsy Index test: whole body MRI, STIR and T1 sequences Patients and setting of diagnosis tests: Screening will be realized on any patient suspected to suffer from inflammatory and addressed for muscle biopsy in one of the participating reference centres for neuro-muscular disorders. -Evaluate if RMI is efficiency to reduce false negative results during a second biopsy.
- Evaluation of reproducibility inter-observers and intra-observers of interpretations of RMI.
- Evaluation of reproducibility inter-observers and intra-observers of muscles biopsy interpretations according with the European neuro muscular classification ENMC.
Study calendar :
- Including 130 patients during 24 months
- RMI interpretations are realised immediately after RMI exam without informing the investigator.
Procedures of anonymisation of the double reading are done every 03 months.
- V1 = inclusion visit Information and non-opposition of patient Collection of demographic, clinical and biological data
- V2 = muscle MRI
- V3 = muscle biopsy
- One year after V1, collection of the final established diagnosis and compare it to the investigator results
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Amiens, France, 80054
- CHU Amiens Nord
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Skin rash typical of dermatomyositis: "lilac" rash (+/- oedemata) of upper eyelids, periungual sign, erythematous-scaly eruption occurring over the MCP and IPP, elbow, knees (Gottron's signs ands papules), erythema of light-sensitive areas OR
- Muscle weakness which is proximal, bilateral and objectifiable by clinical examination ≤ 4/5, and CPK≥2N (N<170).
- Increase CPK and presence of acquired myositis specific antibody
AND
-Onset of troubles ≤3 years
Exclusion Criteria:
- Pregnant female
- Proximal motive neuropathy
- Refusing participation
- Patient under 18 years old
- Adult patient under legal protection
- Patient with contraindication for MRI, pacemaker
- For all other magnetic or ironic implanted equipments, metal workers, must contact PI to ensure their eligibility
- Ocular muscles weakness, isolated dysarthria,
- Patients suffering from toxic myopathy, amyloidosis, inherited muscular dystrophy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: MRI-oriented muscle biopsy
Muscle sample will be done following the usual care.
|
Orientation of muscle biopsy according to the MRI results
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of T1 and STIR (Short Tau Inversion Recovery) sequences of muscle MRI.
Time Frame: between Day 0 and 24 months
|
Description : diagnostic accuracy of muscle MRI (in terms of sensitivity, specificity, predictive positive value and predictive negative value) for the diagnostic of inflammatory myopathy.
|
between Day 0 and 24 months
|
Presence of IIM diagnosed by muscle biopsy
Time Frame: between Day 0 and 24 months
|
Presence of IIM according to ENMC histological criteria
|
between Day 0 and 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of reproductibility intra- versus inter-observers for muscle biopsy interpretation
Time Frame: every 3 months (up to 24 months)
|
Evaluation of reproductibility intra- versus inter-observers for muscle biopsy interpretation according to ENMC (European Neuromuscular Centre) classification (calculation of Kappa coefficients).
|
every 3 months (up to 24 months)
|
Evaluation of reproductibility intra- versus inter-observers for muscle MRI interpretation
Time Frame: every 3 months (up to 24 months)
|
Evaluation of reproductibility intra- versus inter-observers for muscle MRI interpretation (calculation of Kappa coefficients).
|
every 3 months (up to 24 months)
|
Collaborators and Investigators
Investigators
- Principal Investigator: YVES ALLENBACH, MD, PhD, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- K071204
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myositis
-
University of Kansas Medical CenterCompletedInclusion Body Myositis | Sporadic Inclusion Body MyositisUnited States
-
Novartis PharmaceuticalsCompletedSporadic Inclusion Body MyositisUnited States
-
Institut National de la Santé Et de la Recherche...CompletedInclusion Body Myositis (IBM)France
-
La-ser Europe LimitedUnknownSporadic Inclusion Body Myositis
-
Assistance Publique - Hôpitaux de ParisRecruitingInflammatory Myositis | Idiopathic Inflammatory Myositis | Drug-induced Inflammatory MyositisFrance
-
University of Kansas Medical CenterBioSensicsRecruitingInclusion Body MyositisUnited States
-
Abcuro, Inc.Active, not recruitingInclusion Body MyositisAustralia
-
ZevraDenmarkUniversity College, London; University of Kansas Medical CenterTerminatedInclusion Body MyositisUnited States, United Kingdom
-
Novartis PharmaceuticalsCompletedSporadic Inclusion Body Myositis (sIBM)United States
-
Yale UniversityCompletedInclusion Body Myositis | IBMUnited States
Clinical Trials on MRI-oriented muscle biopsy
-
Assiut UniversityNot yet recruitingMyositis | Congenital Myopathy | Acquired Myopathy
-
University Medical Center NijmegenUnknownSepsis | Mechanical VentilationNetherlands
-
Case Comprehensive Cancer CenterWithdrawn
-
Norman MangnerCompletedHeart Failure | Ischemic Myocardiopathy | Dilatative MyocardiopathyGermany
-
University College, LondonM.D. Anderson Cancer Center; Mayo Clinic; Radboud University Medical Center; Sunnybrook... and other collaboratorsCompletedProstate NeoplasmUnited Kingdom
-
University Hospital, LilleUnknown
-
University College, LondonRecruitingProstate CancerUnited States, Canada, Spain, Finland, Argentina, Australia, Belgium, Brazil, Denmark, France, Germany, Italy, Netherlands, Singapore, United Kingdom
-
University Hospital, MontpellierHill-RomTerminatedSpinal Cord Injury | Pressure Ulcer | Paraplegia | BedsoreFrance